Xeltis Overview
- Founded
- 2006
- Status
- Private
- Employees
- 34
- Latest Deal Type
- Series D
- Latest Deal Amount
- $11.7M
- Investors
- 7
Xeltis General Information
Description
Producer of a clinical-stage medical device company intended to provide a restorative approach to cardiovascular therapy. The company's device comprises the bioabsorbable heart valves and blood vessels designed to allow Endogenous Tissue Restoration (ETR) which is the natural restoration of the complex body part they replace upon implantation, enabling the patients body to naturally restore a new blood vessel or heart valve through a therapeutic approach called Endogenous Tissue Restoration (ETR).
Contact Information
Website
www.xeltis.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Other Devices and Supplies
Primary Office
- Seefeldstrasse 69
- 8008 Zurich
- Switzerland
Xeltis Timeline
Xeltis Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series D) | 05-Sep-2019 | $11.7M | 00000 | 000.00 | Completed | Clinical Trials - General |
| 8. Later Stage VC (Series C) | 15-Nov-2017 | 000.00 | 00000 | Completed | Clinical Trials - General | |
| 7. Later Stage VC (Series B) | 27-Nov-2015 | 000.00 | 000.00 | 000.00 | Completed | Generating Revenue |
| 6. Later Stage VC (Series B) | 08-Dec-2014 | 000.00 | 000.00 | 00000 | Completed | Clinical Trials - General |
| 5. Later Stage VC (Series A) | 15-Oct-2013 | 00.00 | 000.00 | 000.00 | Completed | Startup |
| 4. Later Stage VC | 08-May-2012 | 00.000 | 00.000 | 000.00 | Completed | Generating Revenue |
| 3. Early Stage VC | 04-May-2011 | 00.000 | 00.000 | 000.00 | Completed | Generating Revenue |
| 2. Early Stage VC | 16-Nov-2009 | $3.01M | $4.22M | 00.000 | Completed | Startup |
| 1. Early Stage VC | 11-Jul-2008 | $1.21M | $1.21M | 00.000 | Completed | Startup |
Xeltis Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Preferred C1 shares | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | |
| Preferred B shares | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | |
| Preferred B shares | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.00 | |
| Preferred B shares | 000,000 | 00.000000 | 000.0 | 000.0 | 00 | 000.0 | 0.000 | |
| Preferred A Shares | 000,000 | 00.000000 | 000.0 | 000.0 | 00 | 000.0 | 0.00 | |
| Ordinary shares | 00,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | |
| Ordinary shares | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | |
| Ordinary shares | 137,600 | $1.110627 | $24.68 | $24.68 | 1x | $24.68 | 2.68% | |
| Ordinary shares | 30,000 | $1.110627 | $18.51 | $18.51 | 1x | $18.51 | 0.58% |
Xeltis Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Producer of a clinical-stage medical device company intended to provide a restorative approach to cardiovascular therapy
Therapeutic Devices
Zurich, Switzerland
34
As of 2021
00000
00.00
0000-00-00
00000000000
00000
000000
x ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore
00000000000 0000000
Eagan, MN
0000
000000000 -
0000
00 00000
eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia
00000000000 0000000
Singapore, Singapore
000.00
00000000000
000.00
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialXeltis Competitors (17)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cardia | Angel-Backed | Eagan, MN | 0000 | 000000000 - | 0000 | |
| 00 00000000 | Corporate Backed or Acquired | Singapore, Singapore | 000.00 | 00000000000 | 000.00 | |
| 0000000 0000000000 | Venture Capital-Backed | Kirkland, WA | 00 | 00000 | 00000000000 | 00000 |
| 0000000 | Venture Capital-Backed | Clichy, France | 00 | 000.00 | 00000000000 | 000.00 |
| 000000000 0000000 | Formerly VC-backed | Exton, PA | 00 | 000.00 | 000000&0 | 000.00 |
Xeltis Executive Team (31)
Xeltis Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| Christian Wenger Ph.D | Self | Board Member | 000 0000 |
| Clemens Van Blitterswijk Ph.D | Life Sciences Partners | Board Member | 000 0000 |
| Diego Braguglia Ph.D | VI Partners | Board Member | 000 0000 |
| Eliane Schutte | Xeltis | Chief Executive Officer, Board Member & Chief Development Officer | 000 0000 |
| George Fazio | Xeltis | Chairman | 000 0000 |
Xeltis Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialXeltis Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Ysios Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Kurma Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Life Sciences Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| StartAngels Network | Angel Group | Minority | 000 0000 | 000000 0 | |
| VI Partners | Venture Capital | Minority | 000 0000 | 000000 0 |